Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...
dvm3605h
New vaccine protects against feline leukemia virus
The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...
FiercePharma5h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus
Merck Animal Health, a division of Merck & Co., Inc. (MRK), Tuesday announced the expansion of Nobivac NXT vaccine platform with the ...
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...
Pharmaceutical Technology22h
Merck gets grant for genetic markers for clostridium difficile treatment response
Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.